Quick answer
What is ARA 290?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
ARA 290 is a peptide, grouped on this site under Tissue repair peptides, and the 12 research records kept here are 5 from studies in rats or mice, 3 from trials in people and 4 that do not state what kind of study it is.
The literature search returned 26 records. This site keeps 12 of them, which is 46 per cent of what came back.
What it is
This site puts it in the Tissue repair peptides group.
A nonerythropoietic peptide engineered from erythropoietin; the retrieved records report innate immune and tissue-protective endpoints rather than erythropoiesis.[1, 2]
Stated in the titles of the cited 2015 Molecular Medicine and 2016 Transplantation papers.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 3 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 14 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular medicine (Cambridge, Mass.) (2015). pmid:25387363
- A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets. Transplantation (2016). pmid:26683514